Artificial Intelligence (AI) is transforming drug discovery and the life sciences.

By accelerating research, expanding synthetic and analytical capabilities, AI is impacting how scientific insight is translated into products and therapies. As AI becomes increasingly embedded across discovery, development, and clinical workflows, it also introduces a diverse set of legal, regulatory, and ethical considerations that are now central to responsible innovation. Understanding these issues is critical not only for legal professionals, but also for scientists, founders, executives, investors, and institutional leaders working at the forefront of AI-enabled life sciences. 

AI in Drug Discovery and the Life Sciences: IP and Legal Essentials is a six-week seminar series designed to provide participants with a structured, practice-oriented overview of this evolving landscape.

When: 4-5 p.m. Wednesdays, March 4 through April 8, 2026

Where: UCSF Mission Bay Campus